Belite Bio Completes Phase 3 Stargardt Disease Trial
Belite Bio has completed the last subject visit in its pivotal Phase 3 DRAGON trial of tinlarebant for adolescent...
Successful Phase 1 Study for New Alzheimer’s Drug GAL-101
Galimedix reported completion of a Phase 1 study of oral GAL-101 in more than 100 healthy volunteers, showing the...
HCW’s T-Cell Engager Sees Remarkable Primate Study Results
In preclinical testing, a subcutaneously administered, tissue factor–targeting T‑cell engager from HCW Biologics was well tolerated in non‑human primates...
Biosplice Doses First Patient in AML/MDS Clinical Trial
Biosplice has initiated dosing in an NCI-sponsored Phase 1 study of cirtuvivint in relapsed/refractory AML and MDS, testing the...
Apogee Reveals New APG777 Atopic Dermatitis Phase 2 Data
Apogee’s Phase 2 APEX trial of APG777 in moderate-to-severe atopic dermatitis met its primary and secondary endpoints at 16...
Maze’s MZE782 Shows Positive Results for PKU, CKD in Trial
In a randomized, placebo-controlled Phase 1 study in 112 healthy adults, Maze’s SLC6A19 inhibitor MZE782 produced large, dose-dependent pharmacodynamic...
New Dubstent Trial Seeks Better PCI Outcomes for Diabetes
A 120-patient randomized trial in Ireland will compare a hybrid percutaneous coronary intervention strategy—drug-coated balloon angioplasty followed by drug-eluting...
First Patient Dosed in New Glioblastoma/Pancreatic Study
RadioMedix and Vect-Horus have dosed the first patient in an exploratory IND evaluating 203Pb-RMX-VH-PIB, an LDL receptor–targeted SPECT imaging...
Bioxodes Reports Breakthrough Phase 2a Data for Stroke Drug
Primary safety was met in a 23‑patient Phase 2a study of BIOX-101 for intracerebral hemorrhage, with all treated patients...
Dewpoint Closes Series D for Gastric Cancer Clinical Trial
Dewpoint Therapeutics has closed an undisclosed Series D that extends its runway into early 2027 and funds first-in-human development...